Category Archives: Cell Biology

Poem of the week: Ablation by Helen Mort – The Guardian

Ablation

Inside the Northern Generaltheyre trying to burn awaya small piece of your heart.

I want to know which bit,how muchand what it holds.

My questions livebetween what doctors call the heartand what we mean by it,

wide as the gap between brain and mind.And in our lineage of bypassed heartswe should be grateful

for the literal. I know my heartis your heart good for running,not much else

and later as you sit up in your borrowed bedI get the whole thing wrong,call it oblation. Offering

or sacrice. As if youd given something up.As if their tiny re was ritualand we could warm by it.

Not everyone who writes and reads poetry is a horse-drawn arts person, with zero knowledge of the sciences beyond a little light Googling, but there are still plenty of us around. And we shouldnt despise the online toe-dipping so readily available to science outsiders: it can still energise curiosity and develop brain power. The internet is a friendly sort of school: no one will throw you out for being dumb at quadratic equations or, for that matter, tin-eared to prosody. You can forget assessment, progression, humiliation. You can wing across borders. Its all there, and all connectable, time, patience and imagination permitting.

The same day I discovered this weeks poem while browsing online, I had an email from my daughter, quoting some research on angiogenesis that had recently caught her interest. The paper she quoted, based on research by Bentley and Chakravartula on cell behaviour, made a good case for the hypothesis that cell activity is a perception-action process. In other words, that cells engage in a process analogous to a human moving their eyes or their heads or their bodies to create and interact with variables in optic flow. Cells make decisions! I found this exciting and, although Helen Morts poem deals with a different process, cardiac ablation, I think its special connection of the mechanical and emotional had made me far more receptive to the scientific prose. Both disciplines, poetry and cell biology, seemed to jump out of their respective study rooms and embrace like joyously absconding schoolkids. Reading the poem again after the scientific paper was like hearing a beautifully simple song, a melodic and emotional pattern into which the careful precisions of science had been distilled and shaped.

The speaker in Ablation sits at a hospital bedside, wanting answers to the simple, urgent questions people ask at such times. The questions only seem simple, of course. We know, and the speaker knows, that the heart is not a container for feelings and attributes, and the process of ablation is unlikely to burn away love, courage or good cheer but how do we understand these attributes if they have been displaced from their traditional bodily home? Such questions, the speaker rightly says, live / between what doctors call the heart / and what we mean by it, // wide as the gap between brain and mind.

The stanza break above also indicates the gap between the language lay people use about their bodies and minds, and the objective language of medical science. Sometimes I wonder if the constant anguished discussions in the UK about the failures of the NHS arent only practical in origin, but also reflect a profounder sense of underlying problems communication, as if patient and medical professional spoke across each other in different languages.

Morts poem centres on an ancient definition of the heart, now a well-worn metaphor, and does something almost unbelievably fresh with it. The phrase the lineage of bypassed hearts is particularly suggestive. It may allude to a family history of heart-bypass surgery, or to a habitual evasion of emotion. It seems to include a general and well-grounded fear people have of being reduced in their humanity when they become patients.

The speaker in the poem continues to seek a place for the transcendent. An appropriate conceit the misunderstanding of ablation as oblation enables the process. Its a beautifully economical move to retrieve what the narrator most fears will be lost, allowing the tiny fire of the surgical procedure to become ritual and provide both participants with the literal warmth of their shared love, and their sense of its significance.

You dont have to be Richard Dawkins to disagree profoundly with John Keats (a generally wiser and broader thinker than Dawkins) that Isaac Newton destroyed the rainbow by reducing it to a prism. This poem is not condemning medical science, but asking that an imaginative space be kept open. Emotionally, people need ablation and oblation to be allowed to rhyme.

Ablation is from Helen Morts collection No Map Could Show Them (Chatto & Windus, 2016). Reproduced by permission of the author c/o Rogers, Coleridge & White Ltd, 20 Powis Mews, London W11 1JN.

View post:
Poem of the week: Ablation by Helen Mort - The Guardian

Examining the ethics of scientific discovery – Cupertino Today

Posted By: Staff WriterNovember 18, 2019

With artificial intelligence and genetic engineeringcontinuing to shape the future of scientific innovation and discovery,questions about the ethical implications only seem to get more complicated.

Additionally, CRISPR a tool for DNA sequencing and geneediting is bringing new technological changes and advancements in a rapidlyshifting landscape.

A panel discussion at Stanford University later thisweek, moderated by Russ Altman a professor of Bioengineering, Genetics,Medicine, Biomedical Data Science and Computer Science at the university, seeksto discuss how AI and CRISPR are influencing these ethical quandaries and howthey might influence the evolutionary process.

The two panelists for the free, sold-out event areleaders in the field. Jennifer Doudna, a professor of chemistry and molecularand cell biology at UC Berkeley, helped discover CRISPR-Cas9. Fei-Fei Li is acomputer science professor at Stanford in the universitys Institute forHuman-Centered Artificial Intelligence. She previously worked at the schoolsAI Lab and at Google.

The Institute for Human-Centered Artificial Intelligenceis hosting for forum at Stanfords CEMEX Auditorium, 655 Knight Way. It is setfor Tuesday, November 19, from 7 to 8:30 p.m.

While the event has sold out of pre-registration tickets,limited general admission will be available at the site. It will also belivestreamed.

To see more details, click here.

To watch the livestream, click here.

Originally posted here:
Examining the ethics of scientific discovery - Cupertino Today

Everything you need to know about Victoria Beckhams first skincare product launching tomorrow – Evening Standard

The latest lifestyle, fashion and travel trends

He is one of the most googled names in beauty, and she, one of the most prominent figures in fashion.

It was therefore a fitting match for Victoria Beckham to join forces with Augustinus Bader the notoriously publicity-shy director of stem cell biology and cell technology at the University of Leipzig for her first foray in to skincare.

Bader became a household beauty name in February 2018, after the launch of his cult-product The Cream caused convulsions of desire to ripple throughout the beauty industry thanks to its ultra-hydrating and restorative qualities.

And so when looking for a scientific collaborator to join her on her endeavour in to skincare, it seemed a natural fit for the two to merge theircomplementingareas of expertise.

The Cell Rejuvenating Priming Moisturizer (Victoria Beckham Beauty)

Cue the result of the pairing: Victoria Beckham Beautys Cell Rejuvenating Priming Moisturizer.

The moisturiser is the new-and-improved iteration of the Morning Aura Primer Beckham launched as part of her collaboration with Este Lauder in 2016.

The product, which Beckham has re-developed with the help of 59-year-old Bader, is a multifunctional cream thatclaims to prime, impart a glow and also to repair.

Commenting on the collaborative beauty effort, Beckham took to her Instagram page to note: It has been a dream to develop, with Augustinus, a priming moisturizer that works to improve the health of my skin and gives that fresh, natural glow that I love.

Meanwhile Bader said: "It was an honour to collaborate with Victoria for her first Skin launch. I'm excited to share some of our skincare benefits in this product. It's the first product of its kind to care for your skin cells while also preparing your skin for makeup application."

A celebrity facialist has revealed VB's 9-step daily skincare routine

This marks the first skincare product 45-year-old Beckham has launched under her beauty line, which she debuted to critical-acclaim in September, alongside the brands co-founder, Sarah Creal.

Victoria Beckham Beauty has the tagline Luxury Performance, Clean Beauty, and is refusing to pigeonhole itself as just a beauty brand, instead referring to itself as clean beauty movement.

Cell Rejuvenating Priming Moisturizer costs 92 for 30ml and launches tomorrow exclusively at victoriabeckhambeauty.com and augustinusbader.com.

Go here to see the original:
Everything you need to know about Victoria Beckhams first skincare product launching tomorrow - Evening Standard

3D Systems Continues to Announce New Materials – Opening New Production Solutions for Broad Industry Adoption – PRNewswire

VisiJet M2S-HT90 provides best-in-class heat deflection temperature of 90Cwhile meeting USP Class VI 93 standards. Thisstrong, rigid, transparent material is designed for durable goods and automotive applications - ideal for functional prototyping of parts that operate in high temperature environments such as appliances, enclosures and housings, as well as testing parts or assemblies with heated fluids and gasses. Due to its biocompatibility, VisiJet M2S-HT90 is also optimal for healthcare applications including medical devices that include fine features and small internal structures designed for fluid flow.

Biomedical engineers at Antleron (Leuven, Belgium), an R&D company with a mission to enable living therapies, are using 3D Systems' VisiJet M2S-HT90 to develop bioreactors as part of their personalized manufacturing 4.0 strategy. "Antleron is excited to be here in 3D Systems' booth at Formnext to showcase - for the first time - what is in store for next-generation medical applications with the ProJet MJP 2500 Plus printer and VisiJet materials," said Jan Schrooten, chief executive officer, Antleron. "The combined mechanical and biocompatible properties of 3D Systems' VisiJet M2S-HT90 are enabling us to accomplish innovations in cell biology moving from 2D to 3D and beyond. We now can rapidly translate our 'out-of-the-box' cell processing ideas into new ways to develop products for life science applications."

In addition to VisiJet M2S-HT90, Figure 4 PRO-BLK 10, and Figure 4 HI TEMP 300-AMB, the company also announced six additional materials for a range of applications including: Figure 4 EGGSHELL-AMB 10, Figure 4 FLEX-BLK 20, Figure 4 MED-AMB 10, Figure 4 MED-WHT 10, Figure 4 TOUGH-BLK 20 and Figure 4 RUBBER-BLK 10.

3D Systems' also recently announced on November 1 that its new biocompatible denture material, NextDent Denture 3D+, received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The combination of this new dental 3D printing material, NextDent 5100 dental 3D printer, and industry-leading intra-oral scanning and dental software solutions yields an end-to-end digital dentistry solution. As a result, customers can expect more precise,predictable results than through analog techniques - enabling more efficient, cost-effective creation of dentures for patients.

"At Formnext 2019, 3D Systems is showcasing application-specific, production workflow solutions that helpcompanies design and create new and improved products, while gaining efficiencies," said Vyomesh Joshi, president and CEO, 3D Systems. "We collaborate with our customers to design the solution that best fits their needs. This begins with understanding their application, and then selecting the material which will enable production of their desired part. Blending our expertise in materials science, application engineering, 3D printing technology and software allows 3D Systems to deliver unprecedented solutions that keep them ahead of the competition."

For more information about 3D Systems' presence at Formnext 2019, please visit the company's website.

Forward-Looking StatementsCertain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions, and current expectations and may include comments as to the company's beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in the company's periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About 3D Systems More than 30 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading AM solutions company, it empowers manufacturers to create products and business models never before possible through transformed workflows. This is achieved with the Company's best-of-breed digital manufacturing ecosystem - comprised of plastic and metal 3D printers, print materials, on-demand manufacturing services and a portfolio of end-to-end manufacturing software. Each solution is powered by the expertise of the company's application engineers who collaborate with customers to transform manufacturing environments. 3D Systems' solutions address a variety of advanced applications for prototyping through production in markets such as aerospace, automotive, medical, dental and consumer goods. More information on the company is available at http://www.3dsystems.com.

SOURCE 3D Systems

http://www.3dsystems.com

Go here to read the rest:
3D Systems Continues to Announce New Materials - Opening New Production Solutions for Broad Industry Adoption - PRNewswire

Prostate cancer research injects 1.25m of funding to develop treatment – National Health Executive

19.11.19

Prostate Cancer UK and Movember have awarded funding to Queens University Belfast and The University of Manchester to continue progressing treatment for prostate cancer as part of the Belfast-Manchester Centre for Excellence.

With prostate cancer being the most common cancer among males in the UK with more than 47, 500 new diagnoses every year, the funding started back in 2014. Prostate Cancer UK invested 5m to create the first regional Movember Centre of Excellence in partnership between Queens University Belfast and The University of Manchester.

The funding will allow clinical trials to be expanded, develop and pioneer novel treatments while enhancing expert knowledge of this aggressive cancer that affects one in eight men.

Since the formation of the Belfast-Manchester Centre of Excellence (known as FASTMAN) the researchers have established new tests to find high risk patients, and find which patients respond best to numerous treatment options.

Joe OSullivan, Professor of Radiation Oncology at the Centre for Cancer Research and Cell Biology at Queens University Belfast, Co-Director of the Movember Centre of Excellence and Clinical Director of Oncolofy in Belfast Trust explains: We have made huge progress in personalised treatment for prostate cancer patients through the development of new tests to identify the type of tumour, as well as gaining a deeper understanding of the role of radiotherapy in prostate cancer therapy.

Through these new tests, we can potentially identify patients with particularly high-risk prostate cancer to determine what treatment will be most effective, tailored to the particular tumour.

We have also tested several new treatment options through clinical trials which have had encouraging results. We are currently planning to expand availability of these trials to eligible men across the nation. We are proud of the real successes to date and we are delighted to be able to continue this important work.

See the article here:
Prostate cancer research injects 1.25m of funding to develop treatment - National Health Executive

Screening System Designed To Detect Drugs That Block Drivers of Cancer Cell Growth – Technology Networks

A new screening system developed by scientists at the UCLA Jonsson Comprehensive Cancer Center leverages redundancy in an important component of a cell nucleotide metabolism to help identify new drugs that specifically and potently block processes that are essential for cancer cell growth.

BACKGROUND

There are many small molecule kinase inhibitors, such as Gleevec, that have been developed to target cancers and other diseases. However, scientists still dont fully understand the full effects of these drugs. Current screening methods do not capture the effects these inhibitors may have on other components of cells, such as biochemical metabolic networks. Using their understanding of metabolism, the team designed a new high-throughput screening system that allows for identification of selective inhibitors of metabolic pathways.

METHOD

Working with theMolecular Screening Shared Resource at UCLA, the team performed a large scale analyses of 430 kinase inhibitors that have annotated targets within cellular signaling pathways and many of which are currently being used in the clinic. Unexpectedly, multiple inhibitors were found to block nucleotide metabolism and their targets were revealed using mechanistic studies.

IMPACT

This new metabolism-focused screening approach can be a powerful tool in getting new insight into how existing drugs impact metabolic networks and could potentially provide a new understanding into how these drugs are working in the clinic. In addition to characterization of existing compounds that are already being used for treating cancers and other diseases, this screening method could one day also be applied to identify new small molecule modulators of currently un-targeted metabolic pathways not only nucleotide metabolism which can help lead to new drug discoveries.

Reference: Abt, et al. (2019) Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology DOI:https://doi.org/10.1016/j.chembiol.2019.10.012

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post:
Screening System Designed To Detect Drugs That Block Drivers of Cancer Cell Growth - Technology Networks

New Questions About Basic Cell Biology Pdf Answered and Why You Must Read Every Word of This Report – Streetsblog Texas

Essential cell biology pdf is just one of the well-known and best-selling book of Cell Biology. In this time the total amount of DNA doubles per cell. In this time the total amount of DNA per cell doubles.

Mixing Up Things If youve got many courses, you ought to be making separate Cornell notes for every single class. Now you know how to write Cornell notes, its also advisable to learn how to prevent certain mistakes taking these notes. writing a newspaper article If you have additional notes or resources please contribute to the site and help thousands of different people just like you.

It elaborates the fundamental structure of body. There are over 200 distinct varieties of cells in the body. It needs oxygen to make ATP via cell respiration.

The program accommodates students who want to concentrate primarily at the basic science level alongside those who desire to concentrate specifically on innovation like a new device to address a clinical issue. Last projects can be carried out in bigger groups if justified. Credit isnt offered for these course materials, and students https://uk.grademiners.com/article-writing may finish a survey after completing the class.

Thus, its settled that these are books youd like to consult before your exams. If you are entitled, we strongly encourage you to directly take part in the programme. Interested candidates who wish to know more regarding the NEET 2019 syllabus, they can receive the information as provided beneath.

The absolute most basic categorisation of Earths organisms is dependent on different varieties of cells. Its then coiled into a structure known as a chromosome. In cells where theres a high energy demand large quantities of mitochondria are found.

Appendages Bacteria could have these appendages. They are capable of synthesizing new proteins, which are essential for the modulation and maintenance of cellular activities. Mitochondrial cells divide using their very own circular strand of DNA and because of this there may be several mitochondria in 1 cell.

Solutions to the issues can be found at the close of the book. This section makes it possible to briefly sum up http://mlpcenter.edu.vn/professional-proofreading-conspiracy/ the notes on the page of the primary points. These can be discussed in more detail in a subsequent chapter.

Such therapies might also be used during the plan of treatment to slow malignant growth. There are an assortment of functions that are crucial for something to be considered an organism. So it is a basic element of all the living organisms.

An important milestone in the evolution of systems biology has come to be the global project Physiome. A disaccharide includes two monosaccharide units. For instance, some might say the capability to reproduce is a essential trait to indicate life.

Gas exchange is the procedure of swapping one gas for a different. Its also advisable to bear in mind that there are a number of tips that you are able to make the most of to make your work a lot simpler. Doodling Well, lectures may acquire boring sometimes, but youve got to focus.

Organization of the short article is extremely poor. This list consists of online available info and institutions in the area of plant biochemistry. It is possible to download the PDF with the assistance of download link given at the conclusion of this short article.

Here is the original post:
New Questions About Basic Cell Biology Pdf Answered and Why You Must Read Every Word of This Report - Streetsblog Texas

Bayer and Dewpoint Therapeutics Ink $100 Million Research Partnership – BioSpace

Germany-based Bayer and Dewpoint Therapeutics, located in Boston, announced a research deal that could hit $100 million. The research pact will leverage Dewpoints biomolecular condensates technology platform and Bayers small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.

Biomolecular condensates are droplet-like membrane-less organelles that form in a dynamic fashion with many proteins in order to function within cells. About 80% of proteins in humans are considered unreachable with small molecule drugs. The companies believe that with Dewpoints platform, they will broaden the reach of small molecule therapeutics, identifying new drug targets.

As we continue to broaden our capabilities in Research & Development, the collaboration with Dewpoint gives us access to breakthrough innovation potential, said Joerg Moeller, member of Bayers executive committees Pharmaceuticals Division and head of Research and Development. New analytic tools and a growing understanding of biomolecular condensates could provide new insights into cellular functions that previously have not been considered by scientists in drug development, enabling us to identify novel pharmacological targets for future therapies.

Under the terms of the deal, Bayer picks up an option to exclusively license a specific number of novel therapeutics that come out of the research. In addition to access to Bayers small molecule compound library, it brings R&D capabilities including high throughput screening and medicinal chemistry. No other financial details were disclosed. Nor was the length of the pact.

In January 2019, Bayer participated in Dewpoints $60 million Series A financing via the Leaps by Bayer investment unit.

Dewpoint has locations in Boston and Dresden, Germany. Part of the agreement is to expand Dewpoints presence in Germany outside of Dresden.

This partnership is an exciting opportunity to advance treatments for diseases that have long evaded the industry, said Amir Nashat, Dewpoints chief executive officer. We look forward to combining Bayers expertise in chemistry and drug development and Dewpoints novel platform and insights into the role of biomolecular condensates in disease. We also look forward to working closely with Bayer to expand our capabilities in Germany and put the local biotech ecosystem at the forefront of this important and emerging area.

Dewpoint was founded by Anthony Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and Richard Young of the Whitehead Institute in Cambridge, Massachusetts. At the Series A, additional investors besides Bayer included founding investor Polaris Partners, Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, and Alexandria Venture Investments.

Although the research partnership between Dewpoint and Bayer will focus on cardiovascular and gynecologic diseases, numerous other diseases are affected by condensates including cancer, neurodegenerative disorders, immunology and virology.

At the time of the launch, Hyman said, Insights into biomolecular condensates could provide answers to fundamental mysteries in biology, and we are eager to begin using these to discover new therapeutic approaches to diseases.

The companys scientific advisors include Simon Alberti, professor and chair of Cellular Biochemistry at the Technical University Dresden; Arup Chakraborty, Robert T. Haslam Professor of Chemical Engineering and Professor of Physics and Chemistry at MIT; Bradley Hyman, John B. Penny, Jr. Professor of Neurology at Harvard Medical School and Director of the Alzheimers unit at Mass General Institute for Neurological Disease; Rudolf Jaenisch, Whitehead Institute Founding Member and Professor of Biology at MIT; Robert Langer, David H. Koch Institute Professor at MIT; Timothy Mitchison, Hasib Sabbagh Professor of Systems Biology at Harvard Medical School and Director of the Harvard Therapeutics Innovation Hub; and Rohit Pappu, Edwin H. Murty Professor of Engineering in the Department of Biomedical Engineering and Director of the Center for the Science & Engineering of Living Systems at Washington University in St. Louis.

Read this article:
Bayer and Dewpoint Therapeutics Ink $100 Million Research Partnership - BioSpace

Scientists Discover How the Molecule-sorting Station in Our Cells is Formed and Maintained – Nature World News

Nov 16, 2019 08:55 AM EST

The cells in our body are workshops that continuously operate to produce and process substances to keep us going. When a substance enters a cell for processing, it is surrounded by a portion of the cell's outer membrane to form a sac. The sac then buds off into the cell and becomes a vesicle containing the substance. This ingestion of substances by the cell is called endocytosis. The vesicle is then quickly merged with an endosome, an organelle also frequently referred to as a 'sorting station'. From the endosome, the substance is either recycled back to the cell membrane (for exiting the cell) or forwarded to a lysosome--a cell organelle containing enzymes for the breakdown of substances--for degradation. The substances entering a cell--and thereby an endosome--could be nutrients or signal molecules for processing, or even pathogenic viruses which can cause disease. It is therefore extremely important to fully understand the molecular basis of how endosomes are formed and maintained.

It is generally accepted by scholars in the field that these endosomes are formed and maintained by a mechanism in which vesicles travelling from the cell membrane constantly fuse into them. But in a recent study published inCommunications Biology, a group of scientists from Japan and Austria, led by Prof Jiro Toshima from the Tokyo University of Science, claims that vesicles transported out of the Golgi--another crucial cell organelle--and not those from the cell membrane are more important for the formation and maintenance of endosomes. "We used our research to show that endocytic vesicle internalization is not essential, but that vesicle transport from the trans-Golgi network [TGN; the Golgi] is crucial," the team of scientists--comprising Makoto Nagano (Tokyo University of Science), Junko Y. Toshima (Tokyo University of Technology), Daria Elisabeth Siekhaus (Institute of Science and Technology, Austria) and Jiro Toshima--says.

They base their claim on the results of a series of experiments, involving the introduction of mutations or drugs (two drugs called Brefeldin A and Monensin) into yeast cells, to clarify the mechanism of endosome formation. As part of the experiments, they first used mutant yeast strains, which harbor mutations that cause defects in the endocytosis process; that is, they caused the ingestion of substances at the cell membrane to be hampered. Upon observation of the mutated cells, they found that the protein that mediates the formation of endosomes, Rab5, localized at the endosomes as per usual, leading to normal endosome formation.

They then introduced the two drugs into yeast cells to inhibit the transport of specific protein-containing vesicles from the Golgi. By doing so, they expected to find out whether these vesicles are required for the formation and maintenance of endosomes. They saw that smaller amounts of Rab5 localized on the endosomes, hampering endosome formation.

With further similar experiments, Prof Toshima and group saw that certain proteins, which are either resident in the Golgi or recruited to it, are transported from the Golgi to the endosomes where they activate Rab5 and spark the formation of endosomes. Deleting or deactivating the genes crucial to the transport of these proteins from the Golgi ultimately affects endosome formation.

Thus, considering all of these results together, it appears that endocytosis is not necessary for endosome formation and maintenance, but vesicle transport form the Golgi is. "Our results provide a different view of endosome formation and identify the TGN as a critical location for optimal maintenance and functioning of endosomes," Prof Toshima says.

Given that endosomes are essential to the functioning of the cell and, by extension, the organism, understanding the mechanism of its upkeep is important. The results of this compelling study reveal but a fraction of this mechanism and much remains to be discovered. Even so, this advancement in the knowledge of one of the core pathways by which cells process substances in the body can lead to enhanced comprehension of the molecular basis of diseases that involve defective endosomes, thereby leading to better treatments for such diseases.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

Originally posted here:
Scientists Discover How the Molecule-sorting Station in Our Cells is Formed and Maintained - Nature World News

Taking Their Time Together – Harvard Medical School

Husband and wife Hemsley and Lunadel Matthews will retire on November 22 after a combined 61 years of service in the Harvard Medical School Department of Cell Biology.

Hemsley started working at HMS in 1986 as a lab assistant and has been a lab technician group leader since 2012, cleaning and sterilizing the hundreds of tubes, beakers, flasks and other glassware the cell biology labs rely on each day. Lunadel joined Hemsley at HMS in 1992 as a lab aide, and for the past 20 years she has worked as a lab technician, preparing petri dishes, culture media and other materials for experiments.

Get more HMS news here

Lunadel starts her workday at 5:30 in the morning. Its a habit she developed when their children were young. Lunadel would arrive before the sun was up and would begin prepping that days materials for the labs while Hemsley got the children ready for school. Then Lunadel could leave in the afternoon to be home when their children got out of school while Hemsley worked into the evening.

Over their 45 years of marriage and almost 30 years working together at HMS, the couple have made sure to keep their professional and personal lives separate.

We leave Harvard here, said Lunadel. When you go home, you have the children, you have grandkids, you have to give them the best of you. If youre bringing your problems from here home, its not good.

In their retirement, they plan to spend half the year in Boston, where their five adult children and 10 grandchildren live, and half the year in their native Jamaica. When they return to Jamaica, it will be to a life very different from the one they left behind more than four decades ago.

The couple owns two houses in Jamaica, one in Kingston and one in the country, where they keep a small farm with goats, cows and pigs. Asked if they plan to get more animals now that theyll be spending more time in Jamaica, Lunadel shook her head no. Im trying to tone him down, she said, referring to her husband.

Im from the city, so I dont know much about farming, said Hemsley. But when Im out in the air, I just get excited.

After so many years working in cell biology, the Matthews'absence will be felt in the department.

Lunadel and Hemsley are great to work with, said Janelle Frederick, administrative coordinator in cell biology. Theyre conscientious, friendly and easy-going. They take pride in their work each and every day, and thats hard to replicate.

Julie Huang, the departments director of research administration, agreed.

Very few in our department can recall a time that Lunadel and Hemsley werent here. Theyve been wonderful members of our community, and well miss them both, she said.

The couple say they will miss the work and their Harvard colleagues, but theyre excited for this new chapter in their life. In addition to spending more time in Jamaica, they plan to travel, first to Africa, then perhaps Paris, London and anywhere else that strikes their fancy.

Im working from 12 years old, said Hemsley. When I left Jamaica at 23, I said, When I come to America, Im not staying until Im 70.

He will turn70 in January.

So, Ill be 70 in Jamaica, he said.

Its time, echoed Lunadel. Its time for us to do something for ourselves now.

Visit link:
Taking Their Time Together - Harvard Medical School